Followers | 229 |
Posts | 14875 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Sunday, April 24, 2016 9:11:02 PM
I start it in the 8th minute... simply because that's where he first mentions Northwest and gets into the P3 Trial. I had posted a portion of this a few weeks ago, but it was buried in a post where I responded to a fellow poster and perhaps some didn't get a chance to read this. That portion took us up to the point where Dr. Prins speaks of the upcoming partnership of DCVax with one or both of the Big Pharma companies... Bristol Meyers Squibb (BMY) and/or Merck.
You may want to view the video again, as you read the transcription.
https://www.youtube.com/watch?v=GkvsB0rdm3Y
Please forgive any typos.
Here is the first section that I'd posted (for those that already read or grabbed it for the files):
Sounds as if this trial will at least focus on recurrent GBM, as it seems that it is when the tumor is already progressive, that it will benefit from the CI blocking the PD-1 or PDL-1 will help the T-cells, which are already there from DCVax, work.
Here is the next portion of the transcription... taking you through to the 26th minute...
Here's a link to a synopsis of an article published in Science back in May 2015 that seems relevant to these past few paragraphs of Dr. Prins' presentation. You have to have a subscription to view the entire abstract.
http://science.sciencemag.org/content/348/6236/803
And finally, here is the rest of the transcription of Dr. Prins' presentation...
I think that Dr. Prins' conclusions offer us a glimpse as to what is might be involved in the P3 from behind the scenes, as well as and will be happening in the near future. It's obvious he believes immunotherapy will be relevant for GBM in the near future. And as many of us have somewhat figured out here, that while L may be relevant for some patients in the near future (perhaps mesenchymal, pseudo progressors), it may not be as relevant, or at all relevant for all GBM patients. And for those patients, these academics are hoping that a combination trial will make it relevant for them as well.
And finally, targeting the patient-specific neoantigens, and using a dendritic cell vaccine to deliver them will possibly ultimately prove to go further than simply extending life for these GBM patients, it may possibly make them immune to it's return. And who can manufacture a tumor lysate pulsed dendritic cell vaccine in significant quantities?
Why NWBO (along with their pal Cognate).
Hopefully we will be given... sooner rather than later... more than a glimpse of what's going on. In the meantime, you may want to consider buying at these amazingly low share prices while you still can.
:)
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM